JUL 04, 2018 2:45 AM PDT

Identifying New Drug Targets in Therapy-Resistant Cancers

WRITTEN BY: Nouran Amin

Recent research published in the Nature Partner journal Systems Biology and Applications examines how genome-wide data used in collaboration with systems biology analyses can potentially identify master regulators and new drug targets of therapy-resistant cancers.

The findings explain how cancer takes hold and controls certain effector networks, a crucial area for the future of cancer therapy.

 

Cancer researchers are aware of the significance of epigenomic control in development and disease processes. To determine which cellular programs are silent and which are active, epigenomic signals beyond the genetic code of the DNA.

“Epigenomics does not directly affect the DNA itself,” Professor Fabian V. Filipp said. “A hidden layer of regulation controls the activity of genes. In cancer, if we disregard or insufficiently understand epigenomic networks, tumor cells have the ability to rapidly adapt to drug treatment and resistance may arise.”

 

To accomplish target-specificity, epigenetic master regulators in cancer allow target-specificity of their phenotypic program in cooperation with members of the transcriptional machinery. Therefore, the cancer systems biology research team at UC Merced developed a universal workflow for the elucidation of regulatory cooperation networks.

 

“By integrating different genomic features of complementary epigenomic and transcriptomic data, a highly specific and hyperconnected network can be identified,” explains Flipp.

 

Epigenomic target regions can define accessible bile chromatin and determine the target genes.

 

"The research portfolio of Professor Filipp builds an important bridge between clinical and computational sciences," Vice Chancellor for Research Samuel Traina said. "Professor Filipp runs an interdisciplinary research program that serves and positively impacts the educational needs of California's Central Valley".

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
AUG 24, 2020
Immunology
Injectable Drug Stops HIV From Entering Cells
AUG 24, 2020
Injectable Drug Stops HIV From Entering Cells
Once in the body, HIV tracks down T cells that bear the CD4 receptor. It attaches to these immune cells, fusing itself w ...
AUG 06, 2020
Drug Discovery & Development
How Medieval Medicine Can Conquer Modern Day Infections?
AUG 06, 2020
How Medieval Medicine Can Conquer Modern Day Infections?
One of our current global threats is antibiotic resistance.     As more biofilm-associated infections are ...
SEP 21, 2020
Drug Discovery & Development
WHO Endorses Clinical Trials for Herbal Medicines to Treat COVID-19
SEP 21, 2020
WHO Endorses Clinical Trials for Herbal Medicines to Treat COVID-19
The World Health Organization has endorsed a protocol to put African herbal medicines through clinical trials as possibl ...
SEP 20, 2020
Drug Discovery & Development
Cholesterol-Lowering Drugs Reduce The Severity of COVID-19
SEP 20, 2020
Cholesterol-Lowering Drugs Reduce The Severity of COVID-19
Almost a year into the beginnings of the COVID-19 pandemic and we still do not have a Food and Drug Administration (FDA) ...
SEP 30, 2020
Cancer
Chemokines Could be the Key in Controlling Glioma Stem Cells
SEP 30, 2020
Chemokines Could be the Key in Controlling Glioma Stem Cells
The transformation of a healthy cell into a cancerous one often comes with a slew of cellular signaling changes.  T ...
OCT 01, 2020
Immunology
Immune Cells and MS: The Good, the Bad, and the Maybe
OCT 01, 2020
Immune Cells and MS: The Good, the Bad, and the Maybe
Much like electrical wires that are encased in plastic insulating sheaths, nerve cells also are also surrounded by a sim ...
Loading Comments...